Navigation Links
ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
Date:9/30/2008

SYDNEY, Australia, Sept. 30 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that a marketing application for the mucus clearing agent, Bronchitol, has been submitted to the Therapeutic Goods Administration (TGA) division of the Australian Government. If approved, Pharmaxis will be authorized to market Bronchitol in Australia for the treatment of bronchiectasis.

The application is based on a multicentre Phase 3 clinical trial involving more than 360 subjects which evaluated the safety and efficacy of Bronchitol for inhalation in subjects with bronchiectasis. All of the primary efficacy end points were positive and statistically significant, and Bronchitol was shown to be well tolerated with no serious adverse events attributed to treatment.

After being accepted for evaluation, the TGA has 255 working days to review the application lodged by Pharmaxis.

There is currently no approved medication that specifically targets mucus clearance for people suffering from bronchiectasis.

Alan Robertson, Pharmaxis chief executive officer said: "We are delighted to announce this major milestone for Pharmaxis and believe this is an important development for people living with the incurable lung condition bronchiectasis. Pharmaxis is dedicated to the development of safe and effective treatments for airway diseases, and we continue to work closely with regulatory authorities worldwide to bring Bronchitol to patients as quickly as possible."

It is estimated that more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for this patient group in 20 years, addressing an important medical need. In Australia, it is believed that more than 18,000 people live with bronchiectasis and over 70% are moderately or severely incapacitated by their condition.

Bronchitol is also under development
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
2. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
3. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
4. HealthMedia and Aetna to Study Online Insomnia and Depression Interventions
5. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
6. Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity
7. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
8. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
9. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
10. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
11. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... and ST. LOUIS , May ... pressure or high cholesterol may achieve better health outcomes ... according to early results of a unique program conducted ... ESRX ). "Pharmacists are one of the ... interactions with our members presents enormous opportunities to positively ...
(Date:5/5/2015)... 2015 Big Market Research presents a detailed ... Europe , ( France , Germany ... , UK) and Japan . Current scientific views ... provides the 5-year test volume and sales forecasts by country for ... Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed ...
(Date:5/5/2015)... 2015 E-QURE (Electric Quick Ulcer ... premier provider of innovative medical devices in the field ... to shareholders and the investment community, covering 2014 - ... the proprietary Bioelectrical Signal Therapy™ (BST) Device for advanced ... as well as its plans for commercialization and sale ...
Breaking Medicine Technology:SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 42015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 2E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 4E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 5
(Date:5/5/2015)... May 05, 2015 The global lab ... 2020 from $3,474.2 Million in 2014, at an estimated ... segments the lab automation market on the basis of ... and region. On the basis of application, Lab Automation ... solutions, and proteomics solutions. Drug discovery is a major ...
(Date:5/5/2015)... May 05, 2015 Viverae®, a ... Bard Inc., a leading multinational developer, manufacturer and ... fields of vascular, urology, oncology and surgical specialty ... Award. The Vanguard Award recognizes outstanding achievement ... programs among Viverae’s significant client base. , Viverae ...
(Date:5/5/2015)... Dr. Patricia George knows all too well the ... pulmonary hypertension specialist at the University of Pittsburgh Medical ... an initial idea entered her mind for Team PHenomenal ... at the 2010 PHA International Conference,” George recalled. “The ... recalling their climb up Mt. Kilimanjaro and I remember ...
(Date:5/5/2015)... In a April 25, 2015, report published in ... Missouri State Highway Patrol (MSHP) announced that Indiana led the ... the second year in a row. , The MSHP, ... incidents in 2014 alone, around 15% of the national total. ... US Population calls Indiana home, according to the report. , ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Platform that enables businesses to deploy Mobile Engagement Campaigns ... Constant Contact . ProTexting clients can now leverage the ... reach by collecting and syncing subscribers’ e-mail addresses into ... says “We have recognized that the growing trend of ...
Breaking Medicine News(10 mins):Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3
... occurs in sperm could be the key to a new ... an ion channel protein that controls the flow of calcium ... swim, so a drug designed to block the channel would ... in this week's Nature by Dr Arnold Clapham, from the ...
... cell disease is an inherited blood disorder that affects ... red blood cells that contain an abnormal type of ... have difficulty passing through small blood vessels. When sickle-shaped ... is often pain severe enough to require hospital admission. ...
... intestine could hold the key to permanent weight loss. ... is produced in the small intestine in response to ... development of better treatments for eating disorders and obesity. ... and profoundly different from those of traditional appetite suppressants. ...
... that tend to be slightly elevated but still considered ... for suffering from heart disease. Blood pressure readings are ... first number in a blood pressure measurement, represents the ... the diastolic value, represents the pressure when the heart ...
... be mindful of the possible interaction between oral ... Centers for Disease Control and Prevention (CDC) to ... and anti-infective medications, such as Cipro, doxycycline, and ... have been exposed to anthrax spores.// Many antibiotics ...
... significant breakthrough, a team of scientists have successfully transplanted ... diseased one, bringing light to the people who nearly ... about stem cells, in all 33 patients who suffered ... drug and auto-immune diseases causing damage to the part ...
Cached Medicine News:
For the quantitative determination of total protein in serum. Linearity: 1-15 g/dl....
... the quantitative determination of urea ... lag phase of less than ... phase of at least 240 ... 100 mg/dL (35.6 mmol/L urea) ...
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
Medicine Products: